EP Patent

EP2020438A1 — Treatment of pompe's disease

Assigned to Genzyme Corp · Expires 2009-02-04 · 17y expired

What this patent protects

The invention provides methods of treating Pompe's disease using human acid alpha glucosidase. A preferred treatment regime comprises administering greater than 10mg/kg body weight per week to a patient.

USPTO Abstract

The invention provides methods of treating Pompe's disease using human acid alpha glucosidase. A preferred treatment regime comprises administering greater than 10mg/kg body weight per week to a patient.

Drugs covered by this patent

Patent Metadata

Patent number
EP2020438A1
Jurisdiction
EP
Classification
—
Expires
2009-02-04
Drug substance claim
No
Drug product claim
No
Assignee
Genzyme Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.